Revisiting the role of erythropoietin for treatment of ocular disorders

S. L. Shirley Ding, S. N. Leow, R. Munisvaradass, E. H. Koh, Mae-Lynn Catherine Bastion, K. Y. Then, S. Kumar, P. L. Mok

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.

Original languageEnglish
Pages (from-to)1293-1309
Number of pages17
JournalEye
Volume30
Issue number10
DOIs
Publication statusPublished - 1 Oct 2016

Fingerprint

Erythropoietin
Erythropoietin Receptors
Optic Neuritis
Retinopathy of Prematurity
Macular Degeneration
Retinal Detachment
Diabetic Retinopathy
Glaucoma
Glycoproteins
Erythrocytes
Clinical Trials
Hormones

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Shirley Ding, S. L., Leow, S. N., Munisvaradass, R., Koh, E. H., Bastion, M-L. C., Then, K. Y., ... Mok, P. L. (2016). Revisiting the role of erythropoietin for treatment of ocular disorders. Eye, 30(10), 1293-1309. https://doi.org/10.1038/eye.2016.94

Revisiting the role of erythropoietin for treatment of ocular disorders. / Shirley Ding, S. L.; Leow, S. N.; Munisvaradass, R.; Koh, E. H.; Bastion, Mae-Lynn Catherine; Then, K. Y.; Kumar, S.; Mok, P. L.

In: Eye, Vol. 30, No. 10, 01.10.2016, p. 1293-1309.

Research output: Contribution to journalArticle

Shirley Ding, SL, Leow, SN, Munisvaradass, R, Koh, EH, Bastion, M-LC, Then, KY, Kumar, S & Mok, PL 2016, 'Revisiting the role of erythropoietin for treatment of ocular disorders', Eye, vol. 30, no. 10, pp. 1293-1309. https://doi.org/10.1038/eye.2016.94
Shirley Ding SL, Leow SN, Munisvaradass R, Koh EH, Bastion M-LC, Then KY et al. Revisiting the role of erythropoietin for treatment of ocular disorders. Eye. 2016 Oct 1;30(10):1293-1309. https://doi.org/10.1038/eye.2016.94
Shirley Ding, S. L. ; Leow, S. N. ; Munisvaradass, R. ; Koh, E. H. ; Bastion, Mae-Lynn Catherine ; Then, K. Y. ; Kumar, S. ; Mok, P. L. / Revisiting the role of erythropoietin for treatment of ocular disorders. In: Eye. 2016 ; Vol. 30, No. 10. pp. 1293-1309.
@article{e2a64b56a5c44b07a900c68c91c6951f,
title = "Revisiting the role of erythropoietin for treatment of ocular disorders",
abstract = "Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.",
author = "{Shirley Ding}, {S. L.} and Leow, {S. N.} and R. Munisvaradass and Koh, {E. H.} and Bastion, {Mae-Lynn Catherine} and Then, {K. Y.} and S. Kumar and Mok, {P. L.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1038/eye.2016.94",
language = "English",
volume = "30",
pages = "1293--1309",
journal = "Eye",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Revisiting the role of erythropoietin for treatment of ocular disorders

AU - Shirley Ding, S. L.

AU - Leow, S. N.

AU - Munisvaradass, R.

AU - Koh, E. H.

AU - Bastion, Mae-Lynn Catherine

AU - Then, K. Y.

AU - Kumar, S.

AU - Mok, P. L.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.

AB - Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.

UR - http://www.scopus.com/inward/record.url?scp=84990042030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990042030&partnerID=8YFLogxK

U2 - 10.1038/eye.2016.94

DO - 10.1038/eye.2016.94

M3 - Article

C2 - 27285322

AN - SCOPUS:84990042030

VL - 30

SP - 1293

EP - 1309

JO - Eye

JF - Eye

SN - 0950-222X

IS - 10

ER -